Drug Trial Radar · NCT01597440
Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia
Last checked: Nov 20, 2026Latest source record: Apr 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Sep 2012
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Mendel TuchmanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Children's National Research Institute; Boston Children's Hospital; University Hospitals Cleveland Medical Center; University of California, Los Angeles; Children's Hospital of Philadelphia; Lucile Packard Children's Hospital; University of Colorado, Denver
- First posted
- May 14, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 hour, up to 4 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Very few drugs exist that treat hyperammonemia, specifically PA and MMA. Diet restrictions and alternate pathway agents are the current primary treatments, but they frequently fail to prohibit brain damage. Orthotopic liver transplantation cures the hyperammonemia of urea cycle disorders, but organ availability is limited and the procedure is highly invasive and requires life-long immunosuppression. A drug that could repair or stimulate a dysfunctional urea cycle such as this would have several advantages over current therapy. A drug called N-carbamyl-L-glutamate, Carglumic acid (NCG or Carbaglu)has recently been found to be virtually curative of another urea cycle defect called NAGS deficiency. In this disorder, treatment with NCG alone normalizes ureagenesis, blood ammonia and glutamine levels, allows normal protein tolerance and restores health. Knowledge from this study is being applied to acquired hyperammonemia, specifically in patients with propionic PA and MMA, to try and improve neurodevelopmental outcomes by improving the hyperammonemia. Aims: The overall objective of this project is to determine whether treatment of acute hyperammonemia with Carglumic acid in propionic acidemia (PA), methylmalonic acidemia (MMA) changes the long-term outcome of disease and to determine if it is effective in restoring urine ammonia levels to normal levels.
Conditions
- Propionic Acidemia
- Methylmalonic Acidemia
Interventions
N-carbamylglutamateDrug
Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration). The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste. This drug will be administered for 7 days after admission or until discharge (whichever is sooner).
Standard of CareOther
Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- NeurodevelopmentTime frame: 30 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Lucile Packard Children's Hospital at Stanford
Palo Alto, California
The Children's Hospital of Colorado
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
Children's Hospital Boston
Boston, Massachusetts
University Hospitals of Cleveland/Rainbow Babies and Children's Hospital
Cleveland, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.